Chronic Kidney Disease (CKD)

Nephrology·MeSH: Renal Insufficiency, Chronic

Prevalence

15000.0 / 100K

Incidence

500.0 / 100K/yr

19 drugs in development·14 companies·5 clinical trials

Drug Pipeline by Phase

Approved(11)

Drug	Company
cinacalcet	DR REDDYS LABORATORIES LTD (RDY)
doxercalciferol	Amneal Pharmaceuticals, Inc. (AMRX)
EVRENZO (爱瑞卓®) / roxadustat	KYNTRA BIO INC. (KYNB)
inpefa	LEXICON PHARMACEUTICALS, INC. (LXRX)
Jardiance	ELI LILLY & Co (LLY)
Jardiance®	ELI LILLY & Co (LLY)
rayaldee	OPKO HEALTH, INC. (OPK)
sevelamer carbonate	Impax Laboratories, LLC (IPXL)
sevelamer carbonate	DR REDDYS LABORATORIES LTD (RDY)
Vafseo	Akebia Therapeutics, Inc. (AKBA)
XPHOZAH	ARDELYX, INC. (ARDX)

Phase 3(2)

Drug	Company
bardoxolone	REATA PHARMACEUTICALS INC (RETA)
veverimer	Tricida, Inc. (TCDA)

Phase 2(1)

Drug	Company
mze782	Maze Therapeutics, Inc. (MAZE)

Phase 1(1)

Drug	Company
vonsetamig	REGENERON PHARMACEUTICALS, INC. (REGN)

Preclinical(3)

Unknown(1)

Drug	Company
noninterventional	REGENERON PHARMACEUTICALS, INC. (REGN)

BioSniper tracks 19 drugs in development for Chronic Kidney Disease (CKD) across 14 companies.

There are 5 clinical trials targeting Chronic Kidney Disease (CKD) tracked by BioSniper.

The estimated prevalence of Chronic Kidney Disease (CKD) is approximately 15000.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.